Tatyana V Masyuk Selected Research

Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I)

1/2022	Polycystic Liver Disease: Advances in Understanding and Treatment.
1/2017	Therapeutic Targets in Polycystic Liver Disease.
7/2013	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
7/2010	Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
2/2009	Characterization of PKD protein-positive exosome-like vesicles.
1/2009	The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
12/2008	Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
3/2007	Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
10/2003	Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tatyana V Masyuk Research Topics

Disease

14	Polycystic liver disease 01/2022 - 03/2007
13	Cysts 01/2022 - 11/2003
12	Liver Diseases (Liver Disease) 01/2020 - 03/2007
10	Polycystic Kidney Diseases (Polycystic Kidney Disease) 01/2018 - 11/2003
9	Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I) 01/2022 - 10/2003
4	Disease Progression 01/2018 - 03/2007
4	Fibrosis (Cirrhosis) 10/2015 - 03/2007
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 01/2017
3	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2020 - 07/2013
1	Hyperglycemia 01/2020
1	Sclerosing Cholangitis 01/2015
1	Cholangiocarcinoma 01/2015
1	Bardet-Biedl Syndrome (Syndrome, Bardet-Biedl) 02/2009

Drug/Important Bio-Agent (IBA)

10	1-dodecylpyridoxal (PLD)IBA 01/2022 - 03/2012
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2003
5	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2020 - 03/2007
3	pasireotideIBA 01/2020 - 07/2013
3	CalciumIBA 01/2017 - 01/2009
3	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2017 - 03/2007
2	Pharmaceutical PreparationsIBA 01/2018 - 01/2017
2	Small Interfering RNA (siRNA)IBA 01/2018 - 10/2017
2	Adenosine Monophosphate (AMP)IBA 10/2017 - 01/2009
2	Metalloproteases (Metalloproteinases)IBA 01/2017 - 10/2014
2	Bile Acids and Salts (Bile Acids)IBA 10/2015 - 06/2013
2	Octreotide (Sandostatin)FDA LinkGeneric 07/2013 - 03/2007
2	Secretin FDA Link 10/2012 - 12/2008
2	Adenosine (Adenocard)FDA LinkGeneric 01/2009 - 03/2007
1	Histone Deacetylase 6IBA 01/2018
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2018
1	bafilomycin A1IBA 01/2018
1	m-tolyl 5- chloro- 2- (ethylsulfonyl)pyrimidine- 4- carboxylateIBA 10/2017
1	pyrimidineIBA 10/2017
1	Oleanolic AcidIBA 10/2017
1	Taurolithocholic AcidIBA 10/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2017
1	Sirolimus (Rapamycin)FDA Link 01/2017
1	Transient Receptor Potential ChannelsIBA 01/2017
1	cdc25 PhosphatasesIBA 01/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2017
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 10/2015
1	LigandsIBA 01/2015
1	Matrix Metalloproteinase InhibitorsIBA 10/2014
1	marimastatIBA 10/2014
1	ricolinostatIBA 03/2014
1	tubastatin AIBA 03/2014
1	tubacinIBA 03/2014
1	Vitamin K 3 (Menadione)FDA Link 03/2012
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 03/2012
1	Cell Cycle ProteinsIBA 03/2012
1	polycystic kidney disease 2 proteinIBA 02/2009
1	polycystic kidney disease 1 proteinIBA 02/2009
1	ADP-Ribosylation Factors (ADP-Ribosylation Factor)IBA 02/2009
1	erythromycin propionate-N-acetylcysteinateIBA 01/2009
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2009
1	Aquaporins (Water Channels)IBA 12/2008
1	Benzoic Acid (Potassium Benzoate)FDA Link 12/2008
1	SaltsIBA 12/2008
1	AcidsIBA 12/2008
1	Membrane Proteins (Integral Membrane Proteins)IBA 11/2006
1	Amino Acids FDA Link 10/2003

Therapy/Procedure

2	Therapeutics 09/2013 - 03/2012
1	Aftercare (After-Treatment) 10/2017